



Combating Antifungal-Resistant and -Tolerant Fungi in the Clinic

Guest Editors:

Prof. Dr. Cornelia Lass-Flörl
Division of Hygiene and Medical
Microbiology, Medical University
of Innsbruck, Schöpfstraße 41,
6020 Innsbruck, Austria

Dr. Amir Arastehfar
Hackensack Meridian Health
Center for Discovery and
Innovation, Hackensack, Nutley,
NJ 07110, USA

Dr. Erika Shor
Hackensack Meridian Health
Center for Discovery and
Innovation, Hackensack, Nutley,
NJ 07110, USA

Deadline for manuscript
submissions:
closed (31 December 2021)

Message from the Guest Editors

Dear colleagues,

The emergence of drug-resistant and multidrug-resistant (MDR) fungi combined with the limited antifungal armamentarium poses a serious threat to contemporary medicine for the management of invasive infections caused by fungi. Therefore, in this current issue, we aim at highlighting the burden of invasive fungal infections in humans and how drug-resistant and -tolerant fungi have complicated management of IFIs caused by such species.

We encourage papers with a major focus on:

1. Mechanisms underlying antifungal resistance and tolerance
2. New antifungal agents
3. The application of antifungal stewardship in clinic and its association with the burden of drug-resistant fungi
4. New methods to improve the current antifungal susceptibility and tolerance testing protocols to rapidly identify drug-resistant/ tolerant fungi

Moreover, review papers describing the burden of drug resistance and the underlying mechanisms in emerging fungal species are welcome and we encourage reaching out to Dr. Amir Arastehfar.

Keywords: antifungal resistance; antifungal tolerance; identification of antifungal resistance and tolerance; new antifungal agents; antifungal stewardship





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi